Request for Proposals: Accelerating Drug Discovery for Frontotemporal Degeneration

Expire le 13 mai 2024

There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP).

More details